Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Cited by 186

The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.

Improving Dose-Optimization Processes Used in Oncology Drug Development to Minimize Toxicity and Maximize Benefit to Patients

Fourie Zirkelbach, Jeanne, Shah, Mirat, Vallejo, Jonathon, Cheng, Joyce, Ayyoub, Amal, Liu, Jiang, Hudson, Rachel, Sridhara, Rajeshwari, Ison, Gwynn, Amiri-Kordestani, Laleh, Tang, Shenghui, Gwise, Thomas, Rahman, Atiqur, Pazdur, Richard, Theoret, Marc R. · 2022 · Journal of Clinical Oncology

Abstract

This review highlights strategies to integrate dose optimization into premarketing drug development and discusses the underlying statistical principles. Poor dose optimization can have negative consequences for patients, most commonly because of toxicity, including poor quality of life, reduced effectiveness because of inability of patients to stay on current therapy or receive subsequent therapy because of toxicities, and difficulty in developing combination regimens. We reviewed US Food and Drug Administration initial approvals (2019-2021) of small molecules and antibody-drug conjugates for oncologic indications to determine the proportion with a recommended dosage at the maximum tolerated dose or the maximal administered dose, to characterize the use of randomized evaluations of multiple dosages in dose selection, to describe the frequency of dose modifications at the recommended dosage, and to identify case examples that highlight key principles for premarket dose optimization during drug development. Herein, we highlight major principles for dose optimization and review examples of recent US Food and Drug Administration approvals that illustrate how investigation of dose- and exposure-response relationships and use of randomized dose trials can support dose optimization. Although there has been some progress, dose optimization through randomized dose evaluation in oncology trials is not routinely conducted. Dose optimization is essential to ensure that patients receive therapies which maximize efficacy while minimizing toxicity.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1200/jco.22.00371

Cites

3 of 3 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 3 references

Cited by

See all 186

Metadata

Authors
Fourie Zirkelbach, J., Shah, M., Vallejo, J., Cheng, J., Ayyoub, A., Liu, J., Hudson, R., Sridhara, R., Ison, G., Amiri-Kordestani, L., Tang, S., Gwise, T., Rahman, A., Pazdur, R., & Theoret, M. R.
Venue
Journal of Clinical Oncology
Published
2022-10-20
Volume
40
Issue
30
Pages
3489-3500
ISSN
  • 0732-183X (ISSN-L)
  • 1527-7755
OpenAlex
W4295517297
Cited by
186
References
3
FWCI
25.09
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Improving Dose-Optimization Processes Used in Oncology Drug Development to Minimize Toxicity and Maximize Benefit to Patients. https://app.cochat.ai/papers/10.1200/jco.22.00371
The paper
Fourie Zirkelbach, J., Shah, M., Vallejo, J., Cheng, J., Ayyoub, A., Liu, J., Hudson, R., Sridhara, R., Ison, G., Amiri-Kordestani, L., Tang, S., Gwise, T., Rahman, A., Pazdur, R., & Theoret, M. R. (2022). Improving Dose-Optimization Processes Used in Oncology Drug Development to Minimize Toxicity and Maximize Benefit to Patients. Journal of Clinical Oncology. https://doi.org/10.1200/jco.22.00371

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.